GeoVax (GOVX) Research Reports Archive

Research Report Archive Reports from Robert LeBoyer at Noble Capital. Jeffrey Kraws and Karen Goldfarb at Crystal Research....

Ardelyx (ARDX), Raymond James up Price Target, Citigroup Joins the Party.

Wall Street Cozy's up to Ardelyx After New Guidance. On January 8th, Mike Raab, President and Chief Executive...

Is David Dodd on to his Next Billion Dollar Payday for Shareholders?

Huge News: Gedeptin® Therapy Demonstrated Safety, Stabilization and Shrinkage of Treated Tumors. GeoVax (GOVX) Completes Patient...

Happy New Year! Year End Charts.

Expect 2024 to be Year of Both Massive of Gains (and Losses) Plus Massive Volatility. Be Prepared!

Citius Pharmaceuticals, Inc. (CTXR) Reports Fiscal Full Year 2023 Financial Results and Provides Business...

Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024 LYMPHIR™ BLA resubmission on track for early 2024

Pharmather (PHRRF) Has Officially Broken Out.

Read Corporate Presentation Today. Pharmather (PHRRF) which we gave a 'heads-up,' because looked like it was about to break...

Post Reverse Split Mania!

Now Wait a Minute, Aren't Stocks That do Reverse Splits Supposed go Down and Stay Down? First our...

Adding Geovax (GOVX) to 2024 Biotech Watch List.

GEOVAX (GOVX) $0.32 We added this to the Watch List earlier in the...

LQR House (LQR) Commits to Postpone Public Offerings for the Foreseeable Future.

LQR House Initiates Warrants Cancellation and Commits to Postpone Public Offerings for the Foreseeable Future

GeoVax Labs (GOVX) Video Presentation.

GeoVax’s COVID-19 vaccine candidates, which can induce strong antibody and T cell responses against the variants of the SARS-CoV-2 virus, also offers...

Latest article

We’re in Tampa for the Kentucky Derby.

GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we...

Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!